About Syncromune
Syncromune is a private company based in Fort Lauderdale, Florida. It has reported $159,008,791 raised in two offerings on Form D since November 2022. Its chief executive is Eamonn Hobbs.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Dec 3, 2024 | Dec 17, 2024amended May 11, 2026 | $144,828,791fully sold | 77 | $1.8M | EquityRule 506(b) | Form D/A ↗2 earlier filings |
| May 18, 2022 | Nov 29, 2022amended Oct 6, 2023 | $14,180,000of $20.0M target | 44 | $322K | Equity, OptionsRule 506(b) | Form D/A ↗1 earlier filing |
| Total, two offerings | $159,008,791 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Syncromune's Form D filed May 11, 2026.
JG
Jeffrey Cleland
Director
Also a director at Elixirgen Therapeutics and an executive officer, director and promoter at Ironfist Therapeutics and Nanopower Medicine.
Douglas Watson
Lead Independent Director
JM
Joseph Maroon
Director
NS
Norman Schwartz
Director
